沙格列汀治疗单用二甲双胍治疗血糖控制不佳2型糖尿病患者疗效及安全性的研究.docVIP

沙格列汀治疗单用二甲双胍治疗血糖控制不佳2型糖尿病患者疗效及安全性的研究 　　[摘要] 目的 探索沙格列汀?Χ?甲双胍单药治疗血糖控制不佳2型糖尿病患者的安全性及有效性。 方法 选择2015年1月―2016年12月在该院内分泌科门诊及住院的糖尿病患者252例。将入选患者按照1：1的比例随机分配至沙格列汀组或者阿卡波糖组。两组患者均继续维持二甲双胍治疗，沙格列汀组患者在原降糖方案的基础上加用沙格列汀片5 mg/d，1次/d；阿卡波糖组加用阿卡波糖50 mg，3次/d。随访观察期24周。每4周随访1次。观察两组患者治疗前后的FPG、2 hPG、HbA1c的变化，并记录随访期间药物相关不良事件发生情况。比较上述指标的在两组的变化。结果 ①沙格列汀组与阿卡波糖组治疗后FPG、2 hPG较该组治疗前均有明显降低（P0.05）。 结论 对于二甲双胍单药治疗血糖不达标的2型糖尿病患者，加用沙格列汀可有效降糖，提高糖化血红蛋白达标率，且不增加低血糖和胃肠道反应风险。 　　[关键词] 二肽基肽酶抑制剂；沙格列汀；2型糖尿病 　　[中图分类号] R587 [文献标识码] A [文章编号] 1672-4062（2017）05（b）-0103-03 　　[Abstracts] Objective This paper tries to assess the efficacy and safety of saxagliptin on patients with type 2 diabetes with inadequate glycemic control of metformin. Methods 252 patients with type 2 diabetes in this hospital from January 2015 to December 2016 were enrolled in the study. Patients were randomly assigned to the saxagliptin group and acarbose group at a 1： 1 ratio. The patients in the two groups were treated with metformin， and the patients in the saxagliptin group were treated with saxagliptin tablets 5 mg per day and one time a day. The acarbose group was treated with acarbose 50 mg， 3 times a day. Follow-up observation period lasted for 24 weeks， with one follow-up in every 4 weeks. The changes of FPG， 2 hPG and HbA1c before and after treatment were observed and the incidence of drug-related adverse events during the follow-up was recorded. The changes of the above indicators in the two groups were compared. Results ①The levels of FPG and 2 hPG in the saxagliptin group and acarbose group after treatment significantly decreased compared with that before the treatment （P0.05）. Conclusion For patients with type 2 diabetes of inadequately controlled with metformin， the application of saxagliptin can be effectively control the glucose， increase the glycosylated hemoglobin compliance rate， and will not increase the risk of hypoglycemia and gastrointestinal reactions. 　　[Key words] Dipeptidyl peptidase inhibitor； Saxagliptin； Type 2 di